Gufic Biosciences Limited has informed the Exchange regarding Appointment of Mr. Rajesh Kaul as Other of the company w.e.f. July 04, 2025.
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gufic Biosciences has appointed Mr. Rajesh Kaul as Senior President of its Sparsh Cluster, classified as Senior Management Personnel, effective July 4, 2025. The appointment was approved by the Board via circular resolution on July 2, 2025, based on the recommendation of the Nomination & Remuneration Committee. Mr. Kaul brings over 30 years of pharmaceutical industry experience, having held senior leadership roles at Mankind Pharma, Zydus Healthcare, Aristo Pharmaceuticals, Alkem Laboratories, Wockhardt, and Sun Pharma. He has managed P&Ls exceeding ₹500 crore and led teams of 400+ professionals across sales, marketing, and business development.
This is a senior operational hire, not a board-level change, so it is unlikely to move the stock price on its own. However, bringing in a proven pharma leader with deep critical-care and institutional sales experience could strengthen Gufic's Sparsh business cluster and support future growth, which long-term shareholders may view positively.